+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Benign Prostatic Hyperplasia Clinical Trial Pipeline Highlights - 2021

  • ID: 5236273
  • Report
  • January 2021
  • Region: Global
  • Fore Pharma
1 of 3
The latest report Benign Prostatic Hyperplasia Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Benign Prostatic Hyperplasia market. It covers emerging therapies for Benign Prostatic Hyperplasia in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:
The report provides Benign Prostatic Hyperplasia pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:
The report provides Benign Prostatic Hyperplasia pipeline products by their dominant mechanism of action/drug class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:
The report provides Benign Prostatic Hyperplasia pipeline products by the company.

Short-term Launch Highlights:
Find out which Benign Prostatic Hyperplasia pipeline products will be launched in the US and Ex-US till 2025.

SUMMARY:
  • Benign Prostatic Hyperplasia phase 3 clinical trial pipeline products
  • Benign Prostatic Hyperplasia phase 2 clinical trial pipeline products
  • Benign Prostatic Hyperplasia phase 1 clinical trial pipeline products
  • Benign Prostatic Hyperplasia preclinical research pipeline products
  • Benign Prostatic Hyperplasia discovery stage pipeline products
  • Benign Prostatic Hyperplasia pipeline products short-term launch highlights
Note: Product cover images may vary from those shown
2 of 3
1. Benign Prostatic Hyperplasia Pipeline by Stages
2. Benign Prostatic Hyperplasia Phase 3 Clinical Trial Insights
3. Benign Prostatic Hyperplasia Phase 2 Clinical Trial Insights
4. Benign Prostatic Hyperplasia Phase 1 Clinical Trial Insights
5. Benign Prostatic Hyperplasia Preclinical Research Insights
6. Benign Prostatic Hyperplasia Discovery Stage Insights
7. Appendix
8. Research Methodology

List of Tables
Table 1: Benign Prostatic Hyperplasia Phase 3 Clinical Trials, 2021
Table 2: Benign Prostatic Hyperplasia Phase 2 Clinical Trials, 2021
Table 3: Benign Prostatic Hyperplasia Phase 1 Clinical Trials, 2021
Table 4: Benign Prostatic Hyperplasia Preclinical Research, 2021
Table 5: Benign Prostatic Hyperplasia Discovery Stage, 2021

List of Figures
Figure 1: Benign Prostatic Hyperplasia Pipeline Molecules by Clinical Trials Stage, 2021
Figure 2: Benign Prostatic Hyperplasia Phase 3 Clinical Trial Highlights, 2021
Figure 3: Benign Prostatic Hyperplasia Phase 2 Clinical Trial Highlights, 2021
Figure 4: Benign Prostatic Hyperplasia Phase 1 Clinical Trial Highlights, 2021
Figure 5: Benign Prostatic Hyperplasia Preclinical Research Highlights, 2021
Figure 6: Benign Prostatic Hyperplasia Discovery Stage Highlights, 2021
Note: Product cover images may vary from those shown
3 of 3
  • Global
  • Europe
  • US
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Japan
Note: Product cover images may vary from those shown
Adroll
adroll